Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Jun 22, 2022
- Pharmaceuticals
- R&D
Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo Nodularis
TOKYO, June 22, 2022 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma issued a press release on June 22 regarding positive topline results of a phase III clinical study, in prurigo nodularis (OLYMPIA 2) for the humanized anti-human IL-31 receptor A monoclonal antibody nemolizumab, created by Chugai. Clinical development of nemolizumab outside Japan has been conducted by Galderma.
Please refer to the link below for details of the press release:
Galderma announces positive data from phase III trial, demonstrating efficacy and safety of nemolizumab in patients with prurigo nodularis
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Tomoko Shimizu
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
